Korean J Urol.  2011 Sep;52(9):622-625.

Differences in Urinary Stone Composition according to Body Habitus

• Jeong JY
• Doo SW
• Yang WJ
• Lee KW
• Kim JM

Abstract

PURPOSE
We analyzed differences in urinary stone composition according to body mass index (BMI).
MATERIALS AND METHODS
Between January 2007 and December 2010, 505 ureteral or renal stones were collected from 505 patients who underwent surgical intervention. Data on patient age, gender, BMI, urinary pH, and stone composition were collected.
RESULTS
The patients' mean age was 49.2 years (range, 20 to 83 years). Of the 505 patients, 196 (38.7%) had calcium oxalate (CO) stones, 172 (33.9%) had mixed calcium oxalate and calcium phosphate (COP) stones, 72 (14.2%) had calcium phosphate (CP) stones, 50 (9.8%) had uric acid (UA) stones, and 15 (2.9%) had struvite stones. We excluded struvite stones in the statistical analysis because of the small number of patients; a total of 490 patients were included in this study. In the multinomial logistic regression analysis, obesity was found to be associated with UA stones compared with COP stones (odds ratio [OR] 3.488; 95% confidence interval [CI] 1.732-7.025; p<0.001) and CP stones (OR 2.765; 95% CI 1.222-6.259; p=0.015). Similar results were observed for CO stones compared with COP stones (OR 2.682; 95% CI 1.727-4.164; p<0.001) and CP stones (OR 2.126; 95% CI 1.176-3.843; p<0.013).
CONCLUSIONS
Obesity was associated with UA and CO stones compared with the occurrence of COP and CP stones.

Keyword

Body mass index; Obesity; Urinary calculi

MeSH Terms

Body Mass Index
Calcium
Calcium Oxalate
Calcium Phosphates
Humans
Hydrogen-Ion Concentration
Logistic Models
Magnesium Compounds
Obesity
Phosphates
Ureter
Uric Acid
Urinary Calculi
Calcium
Calcium Oxalate
Calcium Phosphates
Magnesium Compounds
Phosphates
Uric Acid

Reference

1. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992. 327:1141–1152.

2. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med. 1995. 98:50–59.

3. Mydlo JH. The impact of obesity in urology. Urol Clin North Am. 2004. 31:275–287.

4. Trinchieri A, Coppi F, Montanari E, Del Nero A, Zanetti G, Pisani E. Increase in the prevalence of symptomatic upper urinary tract stones during the last ten years. Eur Urol. 2000. 37:23–25.

5. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003. 63:1817–1823.

6. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002. 288:1723–1727.

7. Kopelman PG. Obesity as a medical problem. Nature. 2000. 404:635–643.

8. Zilberman DE, Yong D, Albala DM. The impact of societal changes on patterns of urolithiasis. Curr Opin Urol. 2010. 20:148–153.

9. Jung TS, Yang WJ, Song YS. The correlation between metabolic syndrome and urinary pH in adult Korean Men Who visited a health promotion center. Korean J Urol. 2009. 50:694–698.

10. Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001. 60:757–761.

11. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010. 183:2244–2248.

12. Pak CY, Arnold LH. Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med. 1975. 149:930–932.

13. Coe FL, Strauss AL, Tembe V, Le Dun S. Uric acid saturation in calcium nephrolithiasis. Kidney Int. 1980. 17:662–668.

14. Negri AL, Spivacow FR, Del Valle EE, Forrester M, Rosende G, Pinduli I. Role of overweight and obesity on the urinary excretion of promoters and inhibitors of stone formation in stone formers. Urol Res. 2008. 36:303–307.

15. Duffey BG, Pedro RN, Kriedberg C, Weiland D, Melguist J, Ikramuddin S, et al. Lithogenic risk factors in the morbidly obese population. J Urol. 2008. 179:1401–1406.

16. Asplin JR. Obesity and urolithiasis. Adv Chronic Kidney Dis. 2009. 16:11–20.

17. Eisner BH, Porten SP, Bechis SK, Stoller ML. The role of race in determining 24-hour urine composition in white and Asian/Pacific islander stone formers. J Urol. 2010. 183:1407–1411.

18. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet. 2005. 94:1–12.

19. Powell CR, Stoller ML, Schwartz BF, Kane C, Gentle DL, Bruce JE, et al. Impact of body weight on urinary electrolytes in urinary stone former. Urology. 2000. 55:825–830.

20. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004. 65:1422–1425.

21. Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol. 2008. 28:174–180.

22. Agarwal BN, Cabebe FG. Renal acidification in elderly subjects. Nephron. 1980. 26:291–295.

23. Hesse A, Classen A, Knoll M, Timmermann F, Vahlensieck W. Dependence of urine composition on the age and sex of healthy subjects. Clin Chim Acta. 1986. 160:79–86.

24. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens. 2004. 13:181–189.

25. Grases F, Sanchis P, Perelló J, Costa-Bauzá A. Role of uric acid in different types of calcium oxalate renal calculi. Int J Urol. 2006. 13:252–256.

26. Grover PK, Ryall RL. Critical appraisal of salting-out and its implications for chemical and biological sciences. Chem Rev. 2005. 105:1–10.

27. Chou YH, Su CM, Li CC, Liu CC, Liu ME, Wu WJ, et al. Difference in urinary stone components between obese and non-obese patients. Urol Res. 2011. 39:283–287.

28. Murayama T, Sakai N, Yamada T, Takano T. Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: a study in outpatients. Int J Urol. 2001. 8:525–531.

29. Report of a WHO Consultation on obesity: obesity-preventing and managing the global epidemic. 1997. Geneva: WHO/NUT/NCD.